Astellas Signs License For Regeneron's VelocImmune To Bolster Antibody Platform
This article was originally published in PharmAsia News
Executive Summary
Astellas will license Regeneron's human monoclonal antibody discovery technology VelocImmune as part of a strategy to build a new technology platform for the development of antibody drugs, the company said March 30